Doxorubicin chemotherapy for presumptive cardiac hemangiosarcoma in dogs

Sixty‐four dogs were treated with single‐agent doxorubicin (DOX) for presumptive cardiac hemangiosarcoma (cHSA). The objective response rate (CR + PR) was 41%, and the biologic response rate (CR + PR + SD), or clinical benefit, was 68%. The median progression‐free survival (PFS) for treated dogs was...

Full description

Saved in:
Bibliographic Details
Published in:Veterinary & comparative oncology 2016-12, Vol.14 (4), p.e171-e183
Main Authors: Mullin, C.M., Arkans, M.A., Sammarco, C.D., Vail, D.M., Britton, B.M., Vickery, K.R., Risbon, R.E., Lachowicz, J., Burgess, K.E., Manley, C.A., Clifford, C.A.
Format: Article
Language:English
Subjects:
Animals
Antibiotics, Antineoplastic - therapeutic use
Case-Control Studies
chemotherapy
Dog Diseases - drug therapy
Dogs
Doxorubicin - therapeutic use
Female
Heart Neoplasms - drug therapy
Heart Neoplasms - veterinary
Hemangiosarcoma - drug therapy
Hemangiosarcoma - veterinary
Male
metastasis
oncology
Retrospective Studies
small animal
surgical oncology
Survival Analysis
tumour biology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sixty‐four dogs were treated with single‐agent doxorubicin (DOX) for presumptive cardiac hemangiosarcoma (cHSA). The objective response rate (CR + PR) was 41%, and the biologic response rate (CR + PR + SD), or clinical benefit, was 68%. The median progression‐free survival (PFS) for treated dogs was 66 days. The median survival time (MST) for this group was 116 days and was significantly improved compared to a MST of 12 days for untreated control dogs (P = 0.0001). Biologic response was significantly associated with improved PFS (P 
ISSN:1476-5810
1476-5829
DOI:10.1111/vco.12131